• 1
    Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 7639.
  • 2
    Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al, for the Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 163844.
  • 3
    Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 2004; 31: 205561.
  • 4
    Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al, for the Pediatric Rheumatology Collaborative Study Group and the Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 81020.
  • 5
    Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al, for the Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496504.
  • 6
    Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al, for the Paediatric Rheumatology INternational Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010; 69: 71822.
  • 7
    Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term followup on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009; 68: 63541.
  • 8
    Onel KB, Onel K. Anti–tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders [review]. Arthritis Care Res (Hoboken) 2010; 62: 10248.
  • 9
    Yildirim-Toruner C, Kimura Y, Rabinovich E. Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. J Rheumatol 2008; 35: 16801.
  • 10
    Imundo L. Hodgkin's lymphoma associated with anti-TNF use in juvenile idiopathic arthritis: supplemental case report. J Rheumatol 2008; 35: 1681.
  • 11
    Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor α blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010; 62: 251724.
  • 12
    Cron RQ, Beukelman T. Guilt by association—what is the true risk of malignancy in children treated with etanercept for JIA? Pediatr Rheumatol Online J 2010; 8: 23.
  • 13
    Lehman TJ. Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor α blockers change the way we treat children with juvenile idiopathic arthritis? [editorial]. Arthritis Rheum 2010; 62: 21834.
  • 14
    Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 38596.
  • 15
    Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10: R45.
  • 16
    Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692701.
  • 17
    Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, et al. Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 275764.
  • 18
    Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 288695.
  • 19
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009; 60: 31809.
  • 20
    Cleary AG, McDowell H, Sills JA. Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin's lymphoma. Arch Dis Child 2002; 86: 479.
  • 21
    Bernatsky S, Rosenberg AM, Oen KG, Duffy CM, Ramsey-Goldman R, Labrecque J, et al. Malignancies in juvenile idiopathic arthritis: a preliminary report. J Rheumatol 2011; 38: 7603.
  • 22
    Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010; 62: 377682.
  • 23
    Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 32337.
  • 24
    Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 3902.
  • 25
    Petty RE, Cassidy JT. Chronic arthritis in childhood. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders Elsevier; 2011. p. 21135.
  • 26
    Breslow NE, Day NE. Rates and rate standardization. In: Statistical methods in cancer research. Vol. II. The design and analysis of cohort studies. Lyon (France): International Agency for Research on Cancer; 1987. p. 4879.
  • 27
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 91520.
  • 28
    Harrison M, Nordstron B, Gu Y, Mercaldi C, Aquino P, Mines D. Risk of malignancy in biologics-naive juvenile arthritis patients [abstract]. Ann Rheum Dis 2010; 69 Suppl 3: iii631.
  • 29
    Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497502.
  • 30
    Jones OY, Spencer CH, Bowyer SL, Dent PB, Gottlieb BS, Rabinovich CE. A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis. Pediatrics 2006; 117: e8404.
  • 31
    Marwaha RK, Kulkarni KP, Bansal D, Trehan A. Acute lymphoblastic leukemia masquerading as juvenile rheumatoid arthritis: diagnostic pitfall and association with survival. Ann Hematol 2010; 89: 24954.
  • 32
    Harrison M, Cummins C, Horneff G, Southwood TR, Mines D. Cancer risk in juvenile arthritis patients exposed to etanercept: results from three observational cohorts [abstract]. Ann Rheum Dis 2010; 69 Suppl 3: iii147.
  • 33
    MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, Brook RH, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000; 284: 98492.
  • 34
    Gonzalez-Perez A, Fernandez-Vidaurre C, Rueda A, Rivero E, Garcia Rodriguez LA. Cancer incidence in a general population of asthma patients. Pharmacoepidemiol Drug Saf 2006; 15: 1318.
  • 35
    Smith MY, Sobel RE, Wallace CA. Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry. Arthritis Care Res (Hoboken) 2010; 62: 8004.